Alerta

一种靶向骨关节炎H型新生血管的多肽、纳米探针及应用

Resumen de: CN121652293A

本发明属于生物医药技术领域，提供了一种靶向骨关节炎H型新生血管的多肽、纳米探针及应用，所述多肽的氨基酸序列如SEQ ID NO：1所示。本发明提供的多肽及纳米探针可以特异性识别H型新生血管，并克服骨组织递送屏障，为调控骨骼‑血管微环境相互作用开辟新的途径，具有重要的科学意义与临床转化价值。

黄花蒿细胞来源的外泌体纳米囊泡及其内含物过氧化物酶A0A2U1N9S9在制备抗结直肠癌药物中的应用

Resumen de: CN121648271A

本发明公开了黄花蒿细胞来源的外泌体纳米囊泡及其内含物过氧化物酶A0A2U1N9S9在制备抗结直肠癌药物中的应用。经抗CRC活性分析，结果表明黄花蒿细胞来源的外泌体纳米囊泡对DLD‑1和HCT116细胞株的生长具有抑制作用，并基于蛋白质组学技术的差异性分析首次创新性揭示了ACDENVs抑制DLD‑1和HCT116细胞株生长的活性物质基础——过氧化物酶A0A2U1N9S9，为抗结直肠癌药物研究提供了新的研究思路和理论依据。

可离子化脂质及其应用

Resumen de: AU2024307443A1

The present invention provides an ionizable lipid and a drug delivery system comprising the ionizable lipid. Specifically, the present invention provides an ionizable lipid having a structure of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. Lipid nanoparticles constructed by using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small molecule drugs, peptide drugs and protein drugs.

一种仿生纳米平台及其制备方法与应用

Resumen de: CN121648290A

本发明具体公开了一种仿生纳米平台及其制备方法与应用，涉及生物医药技术领域。本发明仿生纳米平台通过构建Ni与LDH的肖特基异质结结构，实现了超声能量到化学能（CO释放）的高效转换。此外，通过肿瘤细胞膜包覆赋予其“同源识别”特性，使其能够主动靶向脑胶质瘤并穿越BBB，实现精准递送与深部肿瘤富集。

一种NIR-Ⅱ多模态光诊疗剂及其制备方法和应用

Resumen de: CN121648318A

本发明公开了一种具有A‑D‑A型兼具多模态成像引导与光动力‑光热协同治疗功能的NIR‑Ⅱ多模态光诊疗剂及其制备方法和应用，其包括结构式如式I所示的化合物，或其药学上可接受的盐、其溶剂化物和其互变异构体。本发明的NIR‑Ⅱ多模态光诊疗材料，结合多模态成像引导和光热‑光动力效应，可以克服现有技术中的诸多局限性，实现对肿瘤、炎症等疾病的高效诊断和治疗，进而推动多模态诊疗技术的发展。

一种金属-多胺纳米复合物及其制备方法与应用

Resumen de: CN121648081A

本发明属于纳米生物材料与肿瘤放射免疫治疗领域，具体涉及一种金属‑多胺纳米复合物及其制备方法与应用。所述纳米复合物是由二价锰离子与亚精胺在油酸介导下通过配位形成疏水核心，并采用DSPE‑PEG进行表面包覆构建而成的核壳结构纳米颗粒。通过二价锰离子与亚精胺的配位组装及DSPE‑PEG表面修饰，实现同步激活cGAS‑STING通路以促进DCs成熟，并增强CD8+ T细胞线粒体脂肪酸氧化功能，增强放疗诱导的抗肿瘤效果。

ヒト化モノクローナル終末糖化産物抗体

Resumen de: JP2024010037A

To provide a humanized monoclonal advanced glycation end-product antibody for therapeutic applications.SOLUTION: A humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell comprises a heavy chain and a light chain. The antibody binds a carboxymethyllysine-modified protein or peptide. A composition comprises a humanized monoclonal antibody that binds to an advanced glycation end-product-modified protein or peptide on a cell and a pharmaceutically acceptable carrier.SELECTED DRAWING: None

イオン化可能な脂質分子およびその調製方法と使用

Resumen de: AU2024231082A1

An ionizable lipid molecule, a preparation method therefor and a use thereof. Specifically, provided are a compound represented by formula I, and a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The definition of each group in the formula is as described in the description. Also provided is a lipid nanoparticle, containing the ionizable lipid compound represented by formula (I). Further provided are a composition and a related use. The compound of formula I can be used to prepare the lipid nanoparticle for delivering a nucleic acid therapeutic agent or an active agent in vivo and in vitro.

薬学的使用のためのＲＮＡ製剤

Resumen de: CN120712350A

The present disclosure relates to an RNA comprising one or more miRNA binding sequences, wherein the one or more miRNA binding sequences bind to a miRNA present in a cell in which expression of the RNA is not desired. After administration, in particular after intramuscular or intravenous administration, the RNA is delivered to a cell such that the polypeptide encoded by the RNA is expressed in certain cells while inhibiting expression in other cells. In some embodiments, such cells comprise endothelial cells. The RNA compositions described herein allow for expression of a pharmaceutically active peptide or polypeptide in a subject by the RNA while reducing or avoiding the risk of undesirable effects caused by expression of the pharmaceutically active peptide or polypeptide in certain cells or tissues.

遺伝子送達ビヒクルの医薬製剤

Resumen de: CN120603600A

The present invention relates to formulations comprising miRNAs having improved stability for use in the treatment of diseases, including neurodegenerative diseases, such as spinal cerebellar ataxia type 3.5.

肺癌用新規腫瘍抗原およびその使用

Resumen de: CN120858107A

Lung cancer is still the main cause of cancer-related death in the world. Although the introduction of an immune checkpoint inhibitor (ICI) makes a significant progress in lung cancer treatment, disease prognosis is still low, and a substantial portion of patients are not responsive to such therapy. The cancer vaccine can potentially provide a complementary approach to enhance anti-tumor immunity and act synergistically with ICI. Described herein are novel tumor antigens common to most lung tumor cells. Several tumor antigens described herein are derived from aberrantly expressed, non-mutated genomic sequences, such as intra-gene sequences and intergene sequences, which are not expressed in normal tissue. Nucleic acids, compositions, cells and vaccines derived from these tumor antigens are described. The use of the tumor antigens, nucleic acids, compositions, cells and vaccines for the treatment of lung cancer is also described.

miR-99b和SIRPα siRNA在制备治疗肝细胞癌的药物中的应用

Resumen de: CN121648077A

本发明公开了包含miR‑99b和SIRPα siRNA的药物组合物在制备用于治疗肝细胞癌及逆转其肿瘤免疫抑制微环境的药物中的应用。所述药物组合物通过将两种核酸药物共同递送至肿瘤相关巨噬细胞，协同发挥将M2型巨噬细胞重编程为M1型以及下调SIRPα蛋白以阻断CD47‑SIRPα“别吃我”信号通路的双重作用，从而增强巨噬细胞吞噬功能、抑制肿瘤生长与转移、促进T细胞浸润，最终有效逆转免疫抑制并激活抗肿瘤免疫应答，所述药物组合物通过经甘露糖修饰且含有二硫键PEG化脂质的脂质纳米粒子实现靶向共递送。

遺伝子改変用薬剤、薬剤送達方法、及び薬剤送達キャリア

Resumen de: US20260062688A1

A drug for genetic modification according to an embodiment is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule and a lipid nanoparticle encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol % or less, and the total amount of the cationic lipid is 60 mol % or less.

NANO-DELIVERY CARRIER

Resumen de: WO2026050897A1

Provided is a stevioside derivative. The stevioside derivative is a compound represented by general formula Ia, or a salt thereof, or a hydrate thereof, or any mixture of the compound represented by general formula Ia, the salt thereof, and the hydrate thereof. In general formula Ia, R1 and R2 are independent of each other. R1 is selected from hydroxyl or glycosyl, and R2 is selected from n-valent rhamnose, rhamnopyranose, mannose, mannopyranose, galactose, galactopyranose, or combinations thereof, or oligosaccharides formed by means of covalent bonding with other sugars, wherein 1 ≤ n ≤ 10, for example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The derivative or an in-vivo metabolite thereof has balanced hydrophilicity and lipophilicity and a multi-triggerable group and can serve as a delivery carrier and/or targeted guiding agent for an active ingredient. Further provided is a preparation method for the derivative and a use of the derivative.

NANOAGONIST, AND PREPARATION METHOD AND USE THEREOF

Resumen de: US20260069654A1

A nanoagonist, and a preparation method and use thereof are provided, belonging to the technical field of nanoscale biomedicine. The nanoagonist is formed by self-assembly of a transformable peptide, where the transformable peptide includes a targeted antimicrobial peptide, a functionalized self-assembling peptide, an FcγR recognition peptide, and a lipase-responsive hydrophobic molecule that are coupled in sequence. The functionalized self-assembling peptide can control the FcγR recognition peptide to flip toward a surface of a target pathogen during secondary self-assembly, and the target pathogen is a pathogen targeted and bound by the targeted antimicrobial peptide. The nanoagonist combines externalization of the FcγR recognition peptide that can be guided during the secondary self-assembly with FcγR-mediated endocytosis, and a nanoagonist is developed for the first time that takes into account both pathogen clearance and host immune function repair.

METHODS FOR PURIFICATION OF IONIZABLE LIPIDS

Resumen de: US20260069712A1

Provided herein are methods for purifying an ionizable amino lipid (IAL) composition comprising impurities that may react with polynucleotides, such as mRNA. Methods for purifying IAL compositions comprise one or more scavenging-removal steps to selectively remove reactive impurities.

SYSTEMS, DEVICES AND METHODS FOR MODULAR FUNCTIONALIZED CELLULAR NANOSTRUCTURES FOR TARGETED PAYLOAD DELIVERY

Resumen de: US20260069711A1

Disclosed are devices, systems, and methods of manufacture and use of modular functionalized cellular nanoparticles that can bind a wide range of ligands, payloads, and functional substances onto a nanoparticle surface. In various embodiments, a cell membrane coating on the nanoparticle is engineered to express a membrane anchor that can readily form a covalent bond with any functional moiety modified with an appropriate peptide tag sequence.

LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES

Resumen de: US20260069714A1

Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.

LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF

Resumen de: US20260069710A1

A liposomal nanocarrier delivery system for targeting an active CD44 molecule, preparation method therefor, and uses thereof. The surface of the liposome is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can be specifically combined with the active CD44 molecule. The liposomal nanocarrier delivery system can be used for preventing, and treating vulnerable plaque or diseases related to vulnerable plaque.

ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF

Resumen de: US20260069698A1

The present invention provides prodrugs and methods of use thereof.

LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF

Resumen de: US20260069684A1

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

NUCLEIC ACID VACCINES ENCAPSULATED WITH NANOALUMINOSILICATE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV)

Resumen de: US20260069675A1

A MERS-CoV vaccine with nucleic acid sequences having at least 90% identity to the spike gene of a MERS-CoV strain as a preventive measure against MERS-CoV infections is described. The nucleic acid sequences may include plasmid DNA (pDNA) or messenger RNA (mRNA) that are encapsulated by aluminosilicates. The aluminosilicates may be functionalized with aminopropyltrimethoxysilanes.

CORONAVIRUS SPIKE PROTEIN-BASED VACCINES

Resumen de: US20260069679A1

Described herein are polypeptides and nanoparticles that display polypeptide sequences, e.g., spike protein domains. In some embodiments, the polypeptides and/or nanoparticles can be used to raise or stimulate an immune response, e.g., as a vaccine.

COMPOSITIONS AND METHODS FOR TREATING VENOUS BLOOD CLOTS

Resumen de: US20260069664A1

Therapeutic compositions for treating a subject, the compositions including a polymeric nanoparticle, an active agent encapsulated within the polymeric nanoparticle, and a delivery vehicle for targeted delivery of the polymeric nanoparticle and encapsulated agent to a target tissue in the subject. The therapeutic compositions can be designed for targeting the destruction of a Nuclei neutrophil extracellular trap (NET) in a venous thrombus in a subject. The active agent can be an enzyme, including deoxyribonuclease 1 (DNase 1) enzyme. Methods of treating a subject using the therapeutic compositions are provided, including methods of treating venous thrombus, deep vein thrombosis, or a related blood clotting disease and/or condition.

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

Nº publicación: US20260069549A1 12/03/2026

Solicitante:

MODERNATX INC [US]
ModernaTX, Inc

Resumen de: US20260069549A1

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.